Release of patients after prostate implantation of iodine seeds (I-125)  by Barquero Sanz, R. et al.
S158 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S141–S163
Rectal dose deposition is negatively inﬂuenced by rectal contrast instillation during HDR-vaginal cuff brachyther-
apy
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Purpose. Bladder ﬁlling variations have shown dosimetrical consequences on organs of risk during vaginal brachytherapy (VBT).
Fewer reports have been focused on the effect of rectal ﬁlling when treating such patients despite this subject has received great
attention on external irradiation. Our aim was to evaluate the inﬂuence of rectal contrast during VBT on rectal dose deposition.
Materials. Treatment plans of 17 patients treated with fractionated postoperative HDR-VBT were reviewed. A CT-scan was under-
gone on each fraction. No special instructions were given to patients. Rectal contrast was administered in some fractions at
discretion of the treating physician. The rectum was contoured from 1 cm above the tip of cylinders to the caudal well position.
Documented rectal doses were D0.1cc, D1cc, D2cc, D5cc and D10cc. Doses were recorded as percentages from the prescribed
dose. Cross sectional area (CSA) was also calculated.
Results. Seventy-four CT-based plans were reviewed, 3–6 per patient (mean 4.7, median 4). Rectal contrast was administered
on the 16% of fractions. Percentages of fractions with contrast per patient: 0–50%. Mean rectal volume: 47.32 cm3 (No contrast:
45.34 cm3, contrast: 57.73; p=0.155). Mean CSA: 9.15 (No contrast: 8.83, contrast 10.87; p=0.83). Mean D0.1cc: 118.26 (No contrast:
115.1, contrast: 134.81). Mean D1cc: 96.83 (No contrast: 93.93, contrast 112.07). Mean D2cc: 87.56 (No contrast: 84.61, contrast:
103.02). Mean D5cc: 71.45 (No contrast: 68.54, contrast: 86.7). Independent non-parametrical test showed signiﬁcance in all rectal
level doses (all p=0.0005).
Conclusions. These results shown a dismal effect related to the presence of rectal contrast. A signiﬁcant increment of rectal doses
was evident over the full length of the rectal DVH. Our data attract suggest the avoidance of that distend the rectum and, if the
data are conﬁrmed, could warrant emptying the rectum before any vaginal cuff brachytherapy fraction.
http://dx.doi.org/10.1016/j.rpor.2013.03.050
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Introduction. Earlobe keloids are being ﬁbrous proliferation due to traumas such as ear piercing, and often prove to be recurrent,
despite the variety of treatments options, especially following a surgical excision. Recurrent keloids are associated with unsightly
cosmetic consequences, particularly in younger patients. Radiotherapy has been achieved to be a successful treatment in recur-
rent cases. External beam radiotherapy is a difﬁcult treatment to be conformed over the earlobe lesions due to its irregular
anatomy, so brachytherapy should be a good option to be considered.
Purpose. We present the patients that have been treated with surgical excision and perioperative HDR brachytherapy in our
institution.
Materials and methods. 11 patients have been treated with perioperative intersticial brachytherapy. In every patient, after a theo-
retical dosimetry was performed, a total dose of 20Gy in 4 fractions of 5Gy was administrated over the surgical scar, separated
6 hours between every fraction, and the total dose was delivered in the ﬁrst 2 days after the surgical excision.
Results. With a follow up of 5 years, no patient suffered a keloid relapse. Grade 1 dermitis was achieved in all patient around 15
days after the brachytherapy treatment that did not maintain more than one month in any case. Grade 1 ﬁbrosis was achieved
in 6 patients. No cases of cronic pruritus were achieved.
Conclusion. Perioperative intersticial HDR brachytherapy is a well tolerated treatment, that obtains an excellent rate of acute local
control in recurrence earlobe keloids.
http://dx.doi.org/10.1016/j.rpor.2013.03.051
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Introduction. For 3 years 370 patients have been treated with I-125 seed prostate implants, releasing the patients after the surgery
implantation. Systematic measurements of dose rate from them were always taken. Aims To assess these data to compare
conclusions with the ICRP 98 Report, which only recommends two months of duration following special instructions if child or
pregnant are in the vicinity of the patient.
Method. Dose rate at 5 and at 50 cm from patient were measured with a SmartION Ion Chamber calibrated in H’(0.07) from 10keV
shield open and H*(10) from 22keV with it shut. To avoid dependence with source depth two conjugate AP and PA views were
taken. To calculate the doses to sleeping partner, children<2 year and workmates, the domestic and standard activities of patient
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were obtained from bibliography. When this preview doses overcame the applicable dose limits (DL) the number of days that the
patient must follow restrictions of permanence with his relatives were calculated.
Results. The variation coefﬁcient (VC) of doses rates among patients was 70% although the VC for the implanted I-125 activity,
was only 23%. For sleeping partner only 38% of treatments no required a period of restrictions of permanence. The maximum
and average values were 153 and 40 days. Analogous values for pregnant and child <2 year were 16%, 161 and 58 days. Analogous
values for work partner were 80%, 68 and 18 days.
Conclusions. The radiation exposures around patients after prostatic implants have variability. Systematic measurements of each
patient in an individualized basis must be done. The 62% and 20% of treatments require period of restrictions to reduce sleeping
partner and working partners doses bellow the DL. A spread sheet has been developed to calculate the day after each implant in
which the domestic activities of the patient can be recovered.
http://dx.doi.org/10.1016/j.rpor.2013.03.052
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Introduction. High Dose Rate Endobronchial Brachytherapy (HDR-EBB) alone or in combination with EBRT, has shown efﬁcacy as
a treatment for inoperable lung neoplasms. In Galicia, this therapeutic modality was launched in 2005 in our centre.
Objectives. To describe our experience with this treatment since its inception to the present (7 years).
Patients and methods. We evaluated the local control, survival and complications at both 1 month and 1 year of all cases treated in
our hospital. A total of 37 tumours were treated in 31 patients, 84% male, mean age of 65 years. 71% of the tumours were located
in the trachea or main bronchi and corresponded mostly (84%) with primary lung cancer. In 20 cases (64.5%) they had curative
intent and 11 (35.5%) palliative intent. On 14 occasions, prior External Beam Radiation Therapy was used and in 7 cases was
associated with other debulking methods. The treatment was applied in weekly fractions of 5Gy. The total dose ranged from 10
to 30Gy in exclusive treatments and 10 to 20Gy when associated with EBRT.
Results. Overall, after a month of treatment, there was clinical improvement in 73.7% and endoscopic improvement in 87%. For
curative treatments, the complete response of the treated area was 70% at 1 month and 66.7% at 1 year. Median survival was 4
months (95% CI 1.8–6.1 months) for palliative treatments and 40 months (95% CI 25.9–54 months) for curative treatments. There
were serious complications in 9.7% of cases, 1 massive hemoptysis, 1 severe bronchospasm and 1 severe arrhythmia.
Conclusion. In our experience, the HDR-EBB, is an effective method for palliative treatment of lung cancer with an acceptable
complication rate. The HDR-EBB with curative intent is a treatment to consider in selected cases. Our results are comparable to
those reported by others.
http://dx.doi.org/10.1016/j.rpor.2013.03.053
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Objective. The aim of study is to describe our experience with high-dose-rate brachytherapy salvage for local prostate cancer
recurrence after radiotherapy.
Materials and methods. We performed descriptive and retrospective study for 4 patients undergoing salvage HDR brachytherapy
for locally recurrent prostate cancer after external radiotherapy between October 2001 and December 2012. With histological
conﬁrmation and negatives extension studies.
Results. Mean age at diagnosis 66.2 years (56–76), median follow-up 103 months (73–122), mean PSA at diagnosis 9.7ng/ml (5.9–13).
Mean Gleason 7 (6–8). One-half of the patients had a high risk according to the criteria D’Amico. Average dose of EBRT was 66.3Gy
(60–70.2), only one patient received brachytherapy boost with HDR. The sequence of treatment in this patient was 60Gy EBRT
and brachytherapy boost 10Gy in two fractions. Finally salvage with 34Gy in 4 fractions of 8.5Gy. In all cases adjuvant hormone
(6–12 months). The mean nadir PSA after EBRT was 0.053ng/ml (0.04–0.08). The median time to biochemical recurrence was 77
months (56–110), with a PSA mean 4ng/ml (1.5–6.7). Positive biopsy in all cases. Brachytherapy HDR rescue using transrectal
ultrasound-guided 29.2Gy mean dose (25.5–34) in 3–4 fractions with interval of 6h. Mean coverage 89% (83–96.5), rectum V70%
1.8Gy (0.34–4.51) in urethra V120% (0%). No complications during treatment. Mean PSA last 0.17ng/ml (0.04–0.58). 2 patients are
alive, free of disease and symptoms, 1 carrier a colostomy for important rectal bleeding, and 1 death non cancer speciﬁc reason.
